Literature DB >> 10770366

Esophageal body length, lower esophageal sphincter length, position and pressure in health and disease.

R E Marshall1, A Anggiansah, C L Anggiansah, W A Owen, W J Owen.   

Abstract

We compared esophageal dimensions in control subjects and patients with differing motility disorders and severities of reflux disease. Patients (1108) and healthy controls (36) underwent manometry and 24-h pH monitoring. Subjects were grouped according to pH and manometry data into seven groups. Mean (s.e.m.) esophageal body length is greatest in achalasia [22.41 (0.27) cm] and least in reflux disease [20.06 (0.13) cm, p < 0.05]. Lower esophageal sphincter (LES) pressure is greatest in achalasia [17.46 (1.06) mmHg] and least in reflux disease [6.57 (0.24) mmHg, p < 0.05]. LES length is least in achalasia patients and control subjects. The ratio of intra-abdominal to intrathoracic LES is greatest in achalasia (1.29), no reflux and normal motility group, and controls and least in reflux disease (1.04, p < 0.05). In conclusion, esophageal body length is greatest in achalasia and least in reflux disease. This is associated with caudal movement of the LES in achalasia and cranial movement of the LES in reflux disease, relative to the diaphragm.

Entities:  

Mesh:

Year:  1999        PMID: 10770366     DOI: 10.1046/j.1442-2050.1999.00060.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  2 in total

1.  Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking.

Authors:  Athanasios Beltsis; Panagiotis Katsinelos; Jannis Kountouras; Nikolaos Kamarianis; Christos Zavos; Agathoklis Pournaras; Dimitrios Kapetanos; Kostas Fasoulas; Chrysanthos Zamboulis; Nikolaos Eugenidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-25       Impact factor: 2.503

Review 2.  Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Authors:  Sebastian F Schoppmann; Ivan Kristo; Martin Riegler
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.